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BACKGROUND: Despite substantial improvements in childhood cancer survival, drug resistance remains problematic for several
paediatric tumour types. The urgent need to access novel agents to treat drug-resistant disease should be expedited by pre-clinical
evaluation of paediatric tumour models during the early stages of drug development in adult cancer patients.
METHODS/RESULTS: The novel cytotoxic RH1 (2,5-diaziridinyl-3-[hydroxymethyl]-6-methyl-1,4-benzoquinone) is activated by the obligate
two-electron reductase DT-diaphorase (DTD, widely expressed in adult tumour cells) to a potent DNA interstrand cross-linker. In
acute viability assays against neuroblastoma, osteosarcoma, and Ewing0s sarcoma cell lines RH1 IC50 values ranged from 1-200nM and
drug potency correlated both with DTD levels and drug-induced apoptosis. However, synergy between RH1 and cisplatin or
doxorubicin was only seen in low DTD expressing cell lines. In clonogenic assays RH1 IC50 values ranged from 1.5–7.5nM and drug
potency did not correlate with DTD level. In A673 Ewing’s sarcoma and 791T osteosarcoma tumour xenografts in mice RH1 induced
apoptosis 24h after a single bolus injection (0.4mg/kg) and daily dosing for 5 days delayed tumour growth relative to control.
CONCLUSION: The demonstration of RH1 efficacy against paediatric tumour cell lines, which was performed concurrently with the adult
Phase 1 Trial, suggests that this agent may have clinical usefulness in childhood cancer.
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Average 5–year survival rates for childhood cancers have
improved dramatically over the past few decades, such that 75%
of children with cancer can now expect to be cured (Gatta et al,
2005). However, cancer remains the second most common cause of
death in children between the ages of 1 and 11 years. Although the
overall survival for this group of patients is excellent, there remain
selected tumour types in which survival is extremely poor, and for
which acquired drug resistance is a major clinical problem. For
example, for children over the age of 1 with stage 4 neuroblastoma,
the best reported 3-year survival is only 55%, despite intensive
chemotherapy, surgery and radiotherapy (Matthay et al, 1999). For
those patients who fail to achieve adequate response to induction
chemotherapy, survival can be expected to be very low (Katzen-
stein et al, 2004). Similarly, poor survival is seen in patients with
metastatic Ewing’s sarcoma and osteosarcoma, despite the vast
majority of patients receiving intensive multi-agent chemotherapy
in international collaborative trials. Thus, an urgent need exists for
novel agents for this group of paediatric cancer patients.
Bioreductive agents are a promising area for anticancer drug
discovery. These pro-drugs are converted to active intermediates
by enzymatic activity either in hypoxic areas of solid tumours
(Sartorelli, 1988) or by increased activity of these enzymes in
tumour compared with normal tissues (Brown and Giaccia, 1998),
and therefore should exhibit tumour-selective cytotoxicity. One- or
two-electron reductases, including cytochrome p450 reductase
(Bligh et al, 1990), NADH cytochrome b5 reductase (Hodnick and
Sartorelli, 1993), and diphtheria toxin-diaphorase (DTD), also
known as NAD(P)H:quinine oxidoreductase (NQ01) (Siegel et al,
1990; Gibson et al, 1992), can activate bioreductive drugs. The two-
electron reductase DTD is particularly interesting, as its activity is
elevated in a wide range of adult tumour types compared with
normal tissue, and is not dependant upon tumour hypoxia
(Cresteil and Jaiswal, 1991; Malkinson et al, 1992; Cummings
et al, 1998). RH1 (2,5-diaziridinyl-3-[hydroxymethyl]-6-methyl-
1,4-benzoquinone) was identified through its very high affinity for
DTD (Beall et al, 1995; Winski et al, 1998). Reduction of RH1
facilitates the formation of GCC sequence-specific DNA inter-
strand cross-linked adducts (Berardini et al, 1993), and the
induction of apoptosis within 6h of exposure (Dehn et al, 2005).
Diphtheria toxin-diaphorase activity and expression correlate with
RH1-induced cytotoxicity in colon cancer and non-small-cell lung
cancer cell lines in vitro (Winski et al, 1998; Sharp et al, 2000). In
the NCI60 tumour cell line panel cell lines expressing NQ01 show
marked sensitivity to RH1, but, in addition, a number of tumour
types, particularly leukaemia and lymphoma cell lines, are
sensitive to RH1 despite relatively low DTD activity (Tudor et al,
2005). RH1 is a substrate for other reductase enzymes, including
cytochrome p450, although recent work suggests that this is
unlikely to play a major role in its activation in cells with normal
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sp450 activity (Begleiter et al, 2007), and that the one-electron
reductase NRH:quinine oxidoreductase 2 (NQ02) may be respon-
sible for the toxicity of RH1 in leukaemia and lymphoma cells (Yan
et al, 2008). RH1 is active against human tumours in xenograft
models in mice (Cummings et al, 2003; Dehn et al, 2004) where
DNA cross-linking could be detected rapidly after RH1 dosing
(Ward et al, 2005). Acquired tumour cell resistance to RH1 seems
to be because of changes in drug uptake/efflux in line with other
diazardinylbenzoquinone-resistant cell lines (T Ward, personal
communication) (Ward et al, 1995).
RH1 has recently completed Phase 1 study in adults in the United
Kingdom and further clinical evaluation is ongoing (Danson et al,
2007a,b). The dose-limiting toxicity in this UK study was
myelosuppression. To date, there has been no report on the efficacy
of RH1 against paediatric tumour cell lines. Here we have
investigated the anti-tumour activity of RH1 against neuroblastoma,
Ewing’s sarcoma, and osteosarcoma cell lines in vitro and against
Ewing’s sarcoma and osteosarcoma xenograft models.
MATERIALS AND METHODS
Paediatric tumour cell lines
The human neuroblastoma cell line pairs, SH-SY5Y and SH-EP1
and LA1-5S and LA1-55n, were kindly provided by Robert Ross
(Fordham University, New York, NY, USA). RDES and A673 ESFT
cells were kindly provided by Sue Burchill (CRUK Clinical
Research Centre, St James’s Hospital, Leeds, UK). The osteosarco-
ma cell lines 791T and U2OS were from the Paterson Institute cell
bank. All cell lines were maintained in RPMI 1640 or DMEM F12
(Gibco, Paisley, UK) supplemented with 10% fetal bovine serum.
Lysates of rhabdomyosarcoma cell lines were kindly provided by
John Anderson (Institute of Child Health, London).
Reagents and chemicals
RH1 was provided by Allos Therapeutics Inc. (Westminster, CO,
USA), and dissolved in DMSO. Other cytotoxic anticancer drugs
were purchased from Sigma-Aldrich (Gillingham, UK).
Clonogenic assays
Clonogenic assays were performed as described earlier (Hussein
et al, 2006). Cells were treated with varying concentrations of RH1
or with cytotoxic agent for 1h, before the medium was aspirated,
cells washed with PBS, and fresh medium added. Plates were
incubated at 371C and 5% CO2 for 7–10 days until visible colonies
(450 cells) were present in the untreated well. All assays were
performed in triplicate. Surviving fraction was calculated as
number of colonies in the test condition/number of colonies in
the untreated well and plotted logarithmically against drug
concentration.
Growth assays
The sulforhodamine B (SRB) assay (Vichai and Kirtikara, 2006)
was used to determine cell growth after exposure to RH1 and
cytotoxic drugs. Cells were plated in exponential growth phase in
96-well plates at densities determined by initial growth curves and
treated with varying concentrations of RH1 or cytotoxic agent for
1h. Five days after drug treatment, when untreated cells were still
in exponential growth phase, cells were fixed and stained before
measuring absorbance at 540nm using a microplate reader
(Labsystems Multiskan EX, MTX Labsystems, Vienna, VA, USA).
All assays were performed in triplicate and IC50 values were
estimated using Calcusyn software (Biosoft, Cambridge, UK).
Immunoblotting
Protein lysates were prepared as described earlier (Hussein et al,
2006) and resolved by SDS polyacrylamide gel electrophoresis and
transferred to PVDF membrane (Immobilon, Millipore, Watford,
UK). Standard immunoblotting procedures were followed with
overnight incubation at 41C with the following primary antibodies:
DT diaphorase 1 in 1000 (David Ross, University of Colorado),
NQO2 1 in 1000 (David Siegel, University of Colorado), PARP
1:1000 (Cell Signalling, Beverly, MA, USA), cleaved caspase 3
1:100 (Cell Signalling), GAPDH 1:2000 (Abcam, Cambridge, UK),
and actin 1:2500 (Sigma-Aldrich). Blots were visualised with the
enhanced chemiluminescence system (GE Healthcare, Little
Chalfont, UK) and analysed on a Fuji LAS-1000 Plus imaging
system with AIDA software (Fuji, Bedford, UK).
DCPIP assay of DTD activity
The DCPIP (2,6-dichlorophenolindophenol) assay was used to
measure functional DTD levels in cell pellets of both the sensitive
and resistant cell lines. Diphtheria toxin-diaphorase activity was
determined by following the spectrophotometric dicoumarol
inhibitable fraction of DCPIP reduction (Traver et al, 1992;
Phillips et al, 1999). Pure recombinant human DTD (kindly
supplied by David Siegel, University of Colorado) was used as a
reference standard (Chen et al, 1992).
Apoptosis assay
Cells were drug treated with RH1 for 1h in exponential growth
phase. After 24h, cells were harvested and adherent and detached
cells were combined. Cells were fixed in 1.2% formaldehyde/48%
glycerol in TRIS/EDTA and nuclei stained with DAPI. The number
of cells with nuclear apoptotic morphology was counted in five
fields of 100 cells. Mean values were calculated from three
independent experiments.
Drug combination studies
Combination Index (CI) methodology was used to evaluate
multiple drug-effect interactions with CalcuSyn software (Biosoft,
Cambridge, UK) (Chou and Hayball, 1996). This uses the multiple
drug-effect equation of Chou and Talalay (1977) derived from
enzyme kinetic models. Additivity between two agents is denoted
by a CI¼0.9–1.1, with synergy and antagonism denoted by
CIo0.9 and CI41.1, respectively (Chou et al, 1994). This method
for assessing synergy takes into account both the potency (Dm or
inhibitory concentration 50% (IC50)) and shape of the concentra-
tion-effect curve. The ratio of RH1 to the cytotoxic agent of interest
was fixed from the IC50 values from the SRB assay. Cells were
treated with RH1 and cytotoxic for 1h. Seven drug concentrations
were used covering the concentration-effect curve. Linear correla-
tion coefficients (r) were generated for each curve to determine the
applicability of the data to the method of analysis. In all
experiments, r was 40.9.
Tumour xenografts
Balb/c-NUDE mice were used for all experiments. For A673
studies, 5 10
6 A673 cells in 0.2ml serum-free RPMI tissue culture
media were implanted by a single subcutaneous (s.c.) injection
into the right flank. For 791T studies, 3 10
6 cells in a 50:50
mixture of serum-free RPMI tissue culture media and matrigel to a
total volume of 0.2ml were implanted s.c. in the right flank.
Tumours were allowed to grow to 200mm
3, at which point
animals were randomly assigned to control or treatment groups.
RH1 treatment consisted of intraperitoneal (i.p.) injection of
0.4mgkg
 1 daily for 5 days as described earlier (Digby et al, 2005).
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sThis magnitude of dose has been shown to produce measurable
DNA cross-linking in xenografted tumour tissue in mice (Ward
et al, 2005). Control mice received 0.2ml of 1% DMSO i.p. daily for
5 days. Mice were housed in an individually ventilated caging
system on a 12-h light/dark environment maintained at constant
temperature and humidity. The animals were fed a standard diet
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Figure 1 Cytotoxicity of RH1 against paediatric tumour cell lines in vitro.( A) Immunoblot showing variation in expression of DTD in paediatric tumour
cell lines (top), activity of DTD is shown beneath, expression of NQ02 in the same cell lines (bottom). GAPDH is shown as a loading control.
(B) Clonogenic response of paediatric tumour cell lines to RH1 in comparison with cisplatin and doxorubicin. (C) SRB response of paediatric tumour cell
lines to RH1 in comparison with cisplatin and doxorubicin. (D) Comparison of IC50 values in paediatric tumour cell lines for RH1, cisplatin and doxorubicin
for clonogenic and SRB assays.
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s(Harlan-Teklad, Madison, WI, USA), and tumour volume (defined
as length width
2 divided by 2) was measured daily. When
tumour volume reached 1250mm
3, the mice were killed by a
schedule 1 method and tumours were excised and formalin fixed
and wax embedded before immunohistochemistry for cleaved
caspase 3 (Cell Signalling). All procedures were carried out in
accordance with UKCCCR guidelines 1999 by approved protocols
(Home Office Project license no. 40-2804).
Statistical analysis
Individual profile plots of tumour volume against days from
randomisation were examined. After taking base 10 logarithms the
plots were well approximated with straight lines. Formal fitting was
then performed using linear mixed effect models, which incorpo-
rated animal-specific random intercepts and slopes. Primary focus
lay in the difference in average slope between the RH1 and control
groups for each tumour type separately. A pooled estimate and test
of this primary parameter was obtained over the two tumour
groups using meta-analysis methods given the estimated effect
sizes and their standard errors.
RESULTS
Diphtheria toxin-diaphorase expression and activity in
paediatric tumour cell lines
We found a range of expression and activity of DTD in tumour cell
lines derived from different paediatric tumours. Of the cell lines
examined, DTD was expressed at highest level in the osteosarcoma
cell line 791T, and at relatively high level in the U2OS osteosarcoma
line (Figure 1A), correlating with their DTD activity. Diphtheria
toxin-diaphorase expression and activity in the two Ewing’s
sarcoma cell lines was lower, but still detectable. In the
neuroblastoma cell lines, DTD expression and activity correlated
with the type of cell line; S-type neuroblastoma cells had elevated
expression and activity compared with their N-type counterparts,
both within the MYCN non-amplified, p53 wild type expressing
SH-EP1 and SH-SY5Y pair, and within the MYCN amplified, p53
deleted LA1-5S and LA1-55n pair. In the N-type neuroblastoma
cell lines, DTD protein expression and activity were very low, and in
SH-SY5Y cells, non-existent. Of six rhabdomyosarcoma cell lines
three, RD, HX170, and T91-95, expressed detectable DTD, whereas
three, SCMC, RMS, and RH18 did not (data not shown). We also
evaluated protein levels of the one-electron reductase NQ02,
recently suggested to be important for the activation of RH1 in
leukaemia and lymphoma cell lines with low levels of DTD
(Yan et al, 2008). NRH:quinine oxidoreductase 2 was detectable in
all of the cell lines examined, although its level varied considerably
across the panel. Expression was highest in 791T osteosarcoma cells,
which also had the highest level of DTD expression and activity.
Importantly, NQ02 expression was detectable in cell lines in which
DTD expression and activity was either absent (SH-SY5Y) or very
low (LA155n), suggesting that NQ02 may have a role in the
activation of RH1 in these cell lines. None of these paediatric
tumour cell lines contained the inactivating single-nucleotide
polymorphism at position 609 (NQ01*2) (Traver et al, 1992) that
results in loss of DTD activity (data not shown).
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Figure 2 Differential induction of apoptosis by RH1 in paediatric tumour cell lines. (A) Differences in SRB IC50 values for RH1 between 791T and U2OS
osteosarcoma cell lines and LA1-5S and LA1-55n neuroblastoma cell lines are reflected in differences in the induction of apoptosis as measured by nuclear
morphology (bar charts) or cleavage of PARP (immunoblots). (B) Similar induction of apoptosis between the Ewing’s sarcoma cell lines A673 and RDES reflects
the lack of difference in SRB IC50 values between these two lines, whether measured by nuclear morphology (bar charts) or cleaved PARP (immunoblots).
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clonogenicity across the paediatric tumour cell line panel
The efficacy of RH1 at inhibiting colony formation was assessed
across the paediatric tumour cell line panel. RH1 potency was
superior to the DNA damaging agent cisplatin, and the topoi-
somerase inhibitor and DNA intercalating agent doxorubicin, both
of which are in widespread clinical use against childhood cancer.
RH1 was the most potent of the three agents examined, with 1000-
fold greater potency than cisplatin, and 19- to 88-fold greater
potency than doxorubicin (Figure 1B). Clonogenic IC50 values for
RH1 varied from 1.5–7.5nM (Figure 1D). There was no correlation
between DTD activity or expression level and sensitivity to RH1 in
the clonogenic assay. The IC50 values for RH1 against SH-SY5Y
neuroblastoma cells, which have no detectable DTD expression or
activity, was 2.5nM, less than that for SH-EP1 neuroblastoma cells
(6nM), which have high level DTD activity, and 791T osteosarcoma
cells (5nM) which showed the highest DTD activity. There was
also no correlation between sensitivity to cisplatin or doxorubicin
and sensitivity to RH1; U2OS osteosarcoma cells and LA-15S
neuroblastoma cells had the same IC50 values to doxorubicin but
varied three-fold in their sensitivity to RH1, and LA-15S and
LA-155n neuroblastoma cells, with the same IC50 values to RH1
varied three-fold in their sensitivity to cisplatin. Thus, RH1 is a
potent inhibitor of clonogenicity in these paediatric tumour cell
lines, and potency is independent of DTD expression or activity.
RH1 inhibited cell population growth in paediatric tumour
cell lines
In keeping with the clonogenic assay results, the comparison of
RH1 with cisplatin and doxorubicin in SRB assay of cell population
growth showed that RH1 was again the most potent agent, with
IC50 values ranging from 1nM for SH-EP1 neuroblastoma cells, to
200nM for U2OS osteosarcoma cells (Figure 1C). RH1 was between
3- and 50-fold more potent in this assay than doxorubicin, and
between 475- and 2000-fold more potent than cisplatin
(Figure 1D). In the SRB assay, sensitivity to cisplatin correlated
well with sensitivity to RH1; the two cell lines that had IC50 values
for cisplatin that were roughly 10-fold higher than for the other cell
lines (LA-15S and U2OS) also had the only IC50 values for RH1
above 40nM. There was no correlation between sensitivity to RH1
and sensitivity to doxorubicin. Although there was no correlation
between expression levels or activity of DTD and sensitivity to
RH1, there was a correlation within cell line pairs. For example,
SH-EP1 neuroblastoma cells, with relatively high DTD activity, had
11-fold greater sensitivity to RH1 than SH-SY5Y neuroblastoma
cells, which had no detectable DTD activity. This 10-fold difference
in sensitivity to RH1 between the high and low DTD-expressing
cell lines was also seen with the LA1-5S/55n neuroblastoma cells
(IC50 11 vs 120nM) and the 791T/U2OS osteosarcoma cells (IC50 26
vs 200nM). The only cell line pair in which there was not a 10-fold
difference in IC50 to RH1 was the Ewing’s sarcoma cell lines, A673
and RDES, in these DTD activity was similar (83 vs
57nMmin
 1mg
 1). Thus, paediatric tumour cell lines are sensitive
to RH1 in an SRB assay of population kinetics, and in this assay,
sensitivity to RH1 correlates with sensitivity to cisplatin, and
within tumour types, with DTD activity.
Differences in sensitivity to RH1 were reflected by
differences in RH1-induced apoptosis
RH1 has been reported to induce apoptosis in adult breast cancer
cell lines. In paediatric tumour cells, RH1 also induced apoptosis
as measured 24h after a 1h drug exposure by immunoblotting for
cleaved PARP and by assessment of classical nuclear apoptotic
morphology (Figure 2). The differential sensitivity to RH1 seen in
the SRB cell population kinetic assay was mirrored by the levels of
RH1-induced apoptosis. Thus, 791T osteosarcoma cells showed
greater cleavage of PARP and higher numbers of apoptotic nuclei
than did U2OS cells over a concentration range (Figure 2A)
correlating with their SRB IC50 values of 26 and 200nM. LA-15S
and LA-155n cells also underwent differential induction of
apoptosis, again correlating with the differences in their SRB
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Figure 3 The combination index (CI) values for combinations of RH1 and cytotoxic agents in paediatric tumour cell lines. (A) Combination index values
for RH1 with cisplatin. (B) Combination index values for RH1 with doxorubicin. CI values of 1 indicate additivity, below 1 indicates synergy, and above 1
indicates antagonism. The lower the CI value the greater the degree of synergism.
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was little difference in their IC50 values by SRB assay, reflected by
similar levels of apoptosis between the two cell lines (Figure 2B).
RH1 was synergistic with cisplatin and doxorubicin in
paediatric tumour cell lines
Earlier studies had shown synergy between RH1 and conventional
cytotoxic agents when administered simultaneously (S Danson,
personal communication). Thus, the effects of the combination of
RH1 with cisplatin or doxorubicin were investigated. The efficacy
of fixed ratio combinations of RH1 and either cisplatin or
doxorubicin was assessed for all eight cell lines again using the
SRB cell population growth assay. Calcusyn software was used to
calculate synergy (low combination index (CI) values), additivity
(CI values around 1), and antagonism (high CI values). Although
strong synergy was seen between RH1 and cisplatin in LA1-55n
neuroblastoma cells, at all three concentration levels tested, this
was not a constant feature across the panel. In SH-EP1 and LA1-5S
neuroblastoma cells RH1 was antagonistic with cisplatin at all
three concentration levels (Figure 3A), and in SH-SY5Y neuro-
blastoma cells and the two osteosarcoma cell lines the drug
interaction was additive, with significant antagonism only at ED90
concentrations in 791T cells. When RH1 was combined with
doxorubicin, evidence of synergy was seen in all cell lines except
791T osteosarcoma cells, in which and in stark contrast, the
combination with RH1 was antagonistic at all concentrations
(Figure 3B). In LA1-55n neuroblastoma cells and U2OS osteo-
sarcoma cells, there was strong synergy between RH1 and doxo-
rubicin at all concentrations. Interestingly, these are the two cell
lines that are least sensitive to RH1 in SRB assay with IC50 values of
120 and 200nM, respectively, compared with a maximum IC50
value of 38nM for the remaining six cell lines.
RH1 induced apoptosis in paediatric tumour xenografts
A single i.p. dose of 0.4mgkg
 1 RH1 was sufficient to induce
apoptosis in A673 Ewing’s sarcoma grown as s.c. xenografts in
nude mice. Figure 4A shows immunostaining for cleaved caspase 3
(CC3) in A673 xenografts with a clear increase in the proportion of
cells expressing CC3 24h after RH1 dosing (Figure 4B), although
this increase was not maintained at later time points. In 791T
osteosarcoma xenografts, however, no increase in percentage of
cells with CC3 was observed at two time points (24 and 48h) after
RH1 treatment, although in these cells the background level of
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Figure 4 Induction of apoptosis in paediatric tumour xenografts. (A) Analysis of cells staining for cleaved caspase 3 in A673 tumour xenografts in nude
mice 24h after a single intraperitoneal dose of RH1. (B) Analysis of cells staining for cleaved caspase 3 in 791T xenografts in nude mice 24h after a single
intraperitoneal dose of RH1.
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have masked any RH1-induced effect (Figure 4B).
RH1 inhibited the growth of paediatric tumour xenografts
A673 Ewing’s sarcoma and 791T osteosarcoma xenografts were
grown to 200mm
3 before random assignment of tumour-bearing
mice to treatment with i.p. injection of RH1 (0.4mgkg
 1)o r
DMSO control daily for 5 days. No differences were observed
between test and control groups of mice in general health or weight
during the course of the experiment, suggesting no general host
toxicity of RH1 treatment. Analysis of individual tumour growth
rates in a mixed linear effects model allowed the slope of tumour
growth to be plotted for each animal (Supplementary Figure 1) and
a mean slope for the group to be calculated (Figures 5A and B).
The difference in tumour growth in RH1- vs vehicle-treated mice
across the two tumour types verged on significance (P¼0.057)
(Figure 5C).
DISCUSSION
This is the first report of the efficacy of RH1 against paediatric
tumour cell lines. The data reported here show that paediatric
tumour cell lines of various types (neuroblastoma, osteosarcoma,
and Ewing’s sarcoma) are exquisitely sensitive to this agent in vitro
where it is more potent than either of the clinically used
conventional DNA damaging agents, cisplatin and doxorubicin.
RH1 was developed as a substrate for the two-electron reductase
DTD, with the aim of selective activation of the agent in tumour
tissue. The absolute requirement for and importance of DTD
activity for the cytotoxic function of RH1 is controversial. Within
modified isogenic pairs of both breast cancer and colon cancer cell
lines, RH1 is clearly more effective against the cells expressing
higher levels of DTD (Winski et al, 1998; Sharp et al, 2000; Dehn
et al, 2005), and indeed such studies have been used to define a
threshold level of DTD activity needed for bioreduction of RH1
and a maximum level of DTD activity above which no further
activation of RH1 will occur (Winski et al, 1998). However, within
the NCI 60 cell line panel, there are cell lines without demonstrable
DTD activity that remain sensitive to this agent (Tudor et al, 2005),
which recent data suggest may be due to the activity of NQ02
within these cell lines (Begleiter et al, 2007). Diphtheria toxin-
diaphorase was variably expressed in the paediatric tumour cell
line panel investigated here, which included the neuroblastoma
line SH-SY5Y, with no demonstrable DTD expression or activity.
As with the NCI 60 panel, no correlation was seen between the
efficacy of RH1 in a clonogenic assay and level of DTD activity.
Even allowing for the reported narrow window of activity of DTD
between threshold and saturation (23–77nMmin
 1mg
 1), two of
the neuroblastoma cell lines studied had DTD activity below this
threshold (SH-SH5Y 0, LA-155n 11), yet had clonogenic IC50 values
for RH1 of 2.5nM, identical to that for LA-15S cells with DTD
activity of 103nMmin
 1mg
 1, well above the suggested saturation
point for maximum RH1 activation (Winski et al, 1998). Thus lack
of DTD activity did not lead to RH1 resistance in paediatric
tumour cell lines, as with leukaemia cell lines in the NCI60 panel
(Tudor et al, 2005), and this may be due to the activity of NQ02,
which was expressed in all of the paediatric tumour cell lines, at
varying levels. In particular, NQ02 expression was detectable in
SH-SY5Y cells, which had no DTD expression or activity yet
retained sensitivity to RH1. Despite the universal potency of
RH1 against paediatric tumour cell lines in clonogenic assay, there
were considerable variations in response using the SRB assay,
where these differences correlated with the levels of RH1-induced
apoptosis. RH1 was a more potent inducer of apoptosis than
either cisplatin or doxorubicin. Efficacy of RH1 in SRB assay
correlated well with efficacy of cisplatin, and within tumour
type the cell line with the higher DTD activity was the more
sensitive to RH1, even when, as with the osteosarcoma cell line
pair, both cell lines had DTD activity above the postulated upper
threshold. It thus seems likely that DTD activity has a role in the
cytotoxicity of RH1 in paediatric tumour cell lines in vitro, but that
other pathways of activation, such as NQ02, are also impor-
tant. The data also suggest that RH1-induced apoptosis cannot
account in full for RH1-mediated reduction in clonogenicity,
implicating other cell fates as contributors to the inhibition of
colony formation.
Earlier studies have shown rapid onset of apoptosis within 6h
of RH1 treatment, increasing up to 48h after drug removal
(Dehn et al, 2005). This is in agreement with the increases in both
apoptotic morphology and cleaved PARP that we observed in
paediatric tumour cell lines 24h after RH1 exposure. Differential
induction of apoptosis between high and low DTD-expressing cell
lines mirrored the differences in sensitivity to RH1 seen in SRB
assay. Apoptosis induction showed a better correlation between
RH1
Control
RH1
Control
–0.1 0.0 0.1 0.2
–0.1
Experiment 1
Experiment 2
Pooled estimate
0.0 0.1 0.2
–0.10 –0.08 –0.06
Difference in average slope (RH1–Control)
–0.04 –0.02 0.00 0.02
P=0.19
P=0.10
P=0.057
Figure 5 Inhibition of growth of paediatric tumour xenografts by RH1.
(A) Mean slopes of tumour growth for individual mice bearing A673
xenografts. Vertical lines represent the group mean. (B) Mean slopes of
tumour growth for individual mice bearing 791T xenografts. Vertical lines
represent the group means. (C) A forest plot of the comparison between
group means for the two experiments, P¼0.057 for the pooled
comparison between RH1 treated and control groups.
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by far the highest DTD activity within the cell line panel and
treatment with RH1 induced almost 40% apoptosis at 24h,
approximately 10% apoptosis in U2OS and LA15S cells with
intermediate DTD levels, and 4% apoptosis in the DTD low-
expressing LA-155n cells (Figure 2A). Although a comparison
of apoptosis at a single time point should not be overinterpreted,
the data imply that RH1 induction of apoptosis over a 24h period
may be facilitated by the rapid activation of RH1 by DTD to
generate proapoptotic cell damage signals. However, as RH1-
mediated reduction of clonogenicity is not DTD dependent, cells
with low/no DTD presumably accumulate sufficient RH1-induced
damage to provoke apoptosis more slowly or RH1 is able to
generate alternative cell fate responses that inhibit colony
formation.
According to the CI, doxorubicin and RH1 were synergistic in
several cell lines, including U2OS osteosarcoma cells, and LA155n and
SH-EP1 neuroblastoma cells. Synergy between RH1 and cisplatin was
only observed in LA155n neuroblastoma cells. Interestingly, U2OS
and LA155n cells, in which the greatest synergy between RH1 and
doxorubicin was observed, were the two most resistant cell lines to
RH1 in the SRB assay, with IC50 values significantly higher than the
other lines (LA-155n 120nM, U2OS 200nM) and were also relatively
resistant to cisplatin. The data suggest that there may be potential
benefit in combining RH1 with other cytotoxic agents. However, these
in vitro methods are merely suggestive of possible synergy in vivo and
the possibility of greater toxicity when combining several DNA
damaging agents needs careful consideration.
In A673 xenografts, RH1 increased the number of apoptotic cells
24h after a single dose of RH1, in agreement with the kinetics of
apoptosis observed in vitro. This level of apoptosis was not
maintained at later time points, suggesting that repeat dosing of
RH1, as used in the in vivo experiments, would be required for
prolonged effect on tumour growth. RH1 inhibited the growth of
both A673 Ewing’s sarcoma and 791T osteosarcoma cells grown as
xenografts in nude mice. This combination of Ewing’s sarcoma
and osteosarcoma xenograft data is reflective of the clinical
situation where RH1 will be initially evaluated against all relapsed
childhood solid tumours.
In conclusion, paediatric tumour cell lines reflecting tumour
types with poor prognosis were sensitive to the novel bio-
reductive agent RH1, regardless of their expression of DTD. In
selected tumour types, RH1 was synergistic with doxorubicin
in vitro. RH1 induced apoptosis in paediatric xenografts grown
in mice, and slowed the growth of these xenografts. This data
supports further investigation of the usefulness of this agent in
the clinic.
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